Skip to content
Evigrade
MajorVitamin K antagonist anticoagulants×Reversible P2Y12 receptor inhibitor

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and a vitamin K antagonist that reduces the formation of active clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation. Its own SmPC classes it as a platelet aggregation inhibitor (ticagrelor SmPC, European Medicines Agency, EMA). The acenocoumarol SmPC lists platelet aggregation inhibitors among drugs that potentiate the anticoagulant or impair haemostasis and increase the risk of bleeding (AEMPS). A study with tolbutamide showed that ticagrelor does not inhibit the CYP2C9 enzyme, so it is unlikely to alter warfarin metabolism (ticagrelor SmPC, EMA). The ticagrelor SmPC does not mention acenocoumarol.

Symptoms

Bleeding in various organs is a common adverse reaction to acenocoumarol, and its risk depends on the dose, the patient's age and the underlying disease (acenocoumarol summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause severe bleeding, including haemorrhagic shock, or fatal bleeding (AEMPS). With excessive anticoagulation the most frequent signs are bleeding into the skin, blood in the urine, haematomas, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, gum bleeding and bleeding into the joints (AEMPS). The most frequently reported adverse reactions with ticagrelor are bleeding and shortness of breath (ticagrelor SmPC, European Medicines Agency, EMA).

Management

Platelet aggregation inhibitors are generally not recommended with acenocoumarol. The acenocoumarol SmPC gives clopidogrel, ticlopidine and acetylsalicylic acid as examples of the class, and ticagrelor belongs to this class according to its own SmPC (acenocoumarol summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS; ticagrelor SmPC, European Medicines Agency, EMA). Use the combination only when it is strictly indicated, for example when there is a concurrent indication for oral anticoagulation and antiplatelet therapy, and then test coagulation more often (AEMPS). Whenever any drug is added or withdrawn, monitor coagulation closely and check it often, for example twice a week (AEMPS). Use ticagrelor with caution in patients who take oral anticoagulants within 24 hours of a ticagrelor dose, and in patients at known high risk of bleeding weigh its benefit against that risk (ticagrelor SmPC, EMA). Give ticagrelor with a low maintenance dose of acetylsalicylic acid, 75–150 mg a day, unless it is contraindicated (EMA), and the acenocoumarol SmPC also lists acetylsalicylic acid among drugs that are generally not recommended with acenocoumarol (AEMPS). Before elective surgery, if an antiplatelet effect is not needed, stop ticagrelor 5 days in advance (EMA), and patients on acenocoumarol need close control of anticoagulation before surgery or invasive procedures (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Ticagrelor